AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Enabling a new era in minimally invasive obesity treatment across Europe
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Subscribe To Our Newsletter & Stay Updated